논문검색
Author Seong-Ho Kong, and Han-Kwang Yang
Place of duty Department of Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Title Surgical Treatment of Gastric Gastrointestinal Stromal Tumor
Publicationinfo Journal of Gastric Cancer 2013 Mar; 013(01): 3-18.
Key_word Gastrointestinal stomal tumors; Surgery; Laparoscopy; Neoadjuvant therapy
Full-Text
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Gastrointestinal stromal tumor is the most common mesenchymal tumor in the gastrointestinal tract and is most frequently developed in the stomach in the form of submucosal tumor. The incidence of gastric gastrointestinal stromal tumor is estimated to be as high as 25% of the population when all small and asymptomatic tumors are included. Because gastric gastrointestinal stromal tumor is not completely distinguished from other submucosal tumors, a surgical excisional biopsy is recommended for tumors >2 cm. The surgical principles of gastrointestinal stromal tumor are composed of an R0 resection with a normal mucosa margin, no systemic lymph node dissection, and avoidance of perforation, which results in peritoneal seeding even in cases with otherwise low risk profiles. Laparoscopic surgery has been indicated for gastrointestinal stromal tumors <5 cm, and the indication for laparoscopic surgery is expanded to larger tumors if the above mentioned surgical principles can be maintained. A simple exogastric resection and various transgastric resection techniques are used for gastrointestinal stromal tumors in favorable locations (the fundus, body, greater curvature side). For a lesion at the gastroesophageal junction in the posterior wall of the stomach, enucleation techniques have been tried preserve the organ's function. Those methods have a theoretical risk of seeding a ruptured tumor, but this risk has not been evaluated by well-designed clinical trials. While some clinical trials are still on-going, neoadjuvant imatinib is suggested when marginally unresectable or multiorgan resection is anticipated to reduce the extent of surgery and the chance of incomplete resection, rupture or bleeding.
출판정보 대한위암학회지 2013 Mar; 013(01): 3-18.

2010 © Copyright Journal Gastric Cancer. All Rights Reserved.
1616 Gwanghwamun Officia, Sinmunno 1-ga, Jongno-gu, Seoul, Korea
Tel: +82-2-730-3760    Fax: +82-2-730-3763    E-mail: jgc@jgc-online.org    Powered by INFOrang.co., Ltd